Investors Cheer AngioDynamics' Q1 Beat, Raised FY22 Sales Outlook

  • AngioDynamics Inc  (NASDAQ: ANGO) reported a Q1 FY22 adjusted EPS loss of $(0.02), ahead of the consensus of $(0.04).
  • Q1 sales increased 9.6% Y/Y to $77 million, beating the analyst consensus of $71.31 million.
  • Endovascular Therapies net sales increased 27.5% to $38.1 million. Oncology net sales improved 13.9% Y/Y to $14 million.
  • Vascular Access net sales declined 11.2% to $25.0 million. Excluding the non-recurring $5.2 million NHS sale in the year-ago period, Vascular Access revenue increased 9.0%.
  • The gross margin for the quarter expanded 120 bps to 52.1%. Adjusted EBITDA was $3.6 million, compared to $4.5 million in 1Q of FY21.
  • AngioDynamics had debt outstanding of $25.0 million on August 31, 2021, versus $20.0 million on May 31, 2021.
  • Guidance: For FY22, AngioDynamics increased sales guidance to $310 million - $315 million (prior guidance of $305 million - $310 million) versus the consensus of $307.8 million.
  • The company expects gross margin to be approximately 55.0% and adjusted EPS of $0.00 - $0.05 (consensus $0.01).
  • Related: AngioDynamics Breaks-Even In FY21, Issues Mixed Forecasts For FY22.
  • Price Action: ANGO stock is up 11.4% at $26.02 during the market session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsLong IdeasNewsGuidanceHealth CareSmall CapMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!